KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab-MedSci.cn

KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab

Herbst, R; Garon, E; Kim, DW; Cho, BC; Gadgeel, S; Lena, H; Gurpide, A; Han, JY; Arvis, CD; Majem, M; Forster, M; Monnet, I; Novella, S; Saka, H; Szalai, Z; Gubens, M; Su, WC; Lubiniecki, G; Shentu, Y; Ferraro, G; Baas, P

JOURNAL OF THORACIC ONCOLOGY, 2017; 12 (1): S254

科室
- - 订阅+
  - 更多科室
工具
服务